# CAR-T Re-treatment for Refractory/Relapsed Multiple Myeloma

> **NCT03672253** · PHASE1 · UNKNOWN · sponsor: **Second Affiliated Hospital of Xi'an Jiaotong University** · enrollment: 20 (estimated)

## Conditions studied

- Multiple Myeloma
- Multiple Myeloma in Relapse
- Multiple Myeloma Progression

## Interventions

- **DRUG:** CAR-T Re-treatment

## Key facts

- **NCT ID:** NCT03672253
- **Lead sponsor:** Second Affiliated Hospital of Xi'an Jiaotong University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-07-26
- **Primary completion:** 2020-12-31
- **Final completion:** 2020-12-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2018-12-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03672253

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03672253, "CAR-T Re-treatment for Refractory/Relapsed Multiple Myeloma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03672253. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*